Navigation Links
Lo studio EXAMINE della Takeda sulla sicurezza cardiovascolare di alogliptin in aggiunta alla terapia standard ha soddisfatto l'endpoint primario di non inferiorità rispetto al placebo dimostrando che non si verifica nessun incremento del rischio ca
Date:9/17/2013

uppo trattato con alogliptin e in quello trattato con placebo, e la differenza delle medie least square di HbA1c tra alogliptin e placebo è stata di -0,36% (95% CI, -0,43, -0,28, p<0.001). Nell'analisi dei componenti dell'endpoint primario le hazard ratio erano coerenti con i risultati globali. Le hazard ratio per morte per tutte le cause e per morte per cause cardiovascolari erano coerenti con l'endpoint primario composito.

Takeda ha condotto lo studio globale EXAMINE in conformità con quanto previsto dalla Guida 2008 della Food and Drug Administration (FDA) degli Stati Uniti (US), dal titolo "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes", per tutti i nuovi trattamenti per il diabete di tipo 2. Trattandosi di uno studio globale, i risultati di EXAMINE saranno condivisi con le agenzie regolatorie una volta completate tutte le analisi, come appropriato.

Informazioni sul diabete di tipo 2
Il diabete di tipo 2 è la forma più comune di diabete che interessa milioni di persone in tutto il mondo. Il diabete di tipo 2 è una condizione cronica e progressiva e i pazienti devono lavorare insieme a professionisti della sanità per gestire e monitorare la loro patologia. In aggiunta alla dieta e all'esercizio fisico, i pazienti devono spesso assumere uno o più medicinali che li aiutino a controllare i livelli di glucosio nel sangue. Secondo la International Diabetes Federation, la spesa sanitaria mondiale per il diabete (sia di tipo 1 che di tipo 2) è stata stimata maggiore di 471 miliardi di dollari USA nel 2012. Entro il 2030, si prevede che questa cifra supererà i 595 miliardi di dollari US.

Informazioni su Alogliptin
Alogliptin è un inibitore del dipeptidil peptidasi-4 (DPP-4i) per il trattamento del diabete di tipo 2 negli adulti, in aggiunta alla dieta e all'esercizio fisico. I DPP-
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Anthony Creed Joins DDSTUDIO As GM, Experience Design
2. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
3. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
4. I benefici della tecnologia Hologic per lutilizzo della Tomosintesi in vengono corroborati dalla pubblicazione di uno studio italiano
5. Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
6. River City Laser Tattoo Removal Studio Offers Grand Opening Discounts on Treatments Using the Astanza Revolution Laser
7. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
8. New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments
9. Study Examines Smart Pharma Strategies for Effective Messaging around New Products and the Medical Conditions they Treat
10. TeamHealth White Paper Examines Telemedicine Risks, Risk Management Strategies
11. The Food Journal Examines Dietary Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... of units of common stock and warrants at a ... $20 million, prior to deducting underwriting discounts and commissions ... and warrants are immediately separable and will be issued ... begin trading on The NASDAQ Stock Market under the ...
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014 /PRNewswire/ ... IT services company, announced today that it has ... Records (EMR) solution for Plastic Surgery and Dermatology ... provide even more value to healthcare practices using ... CEO of eRelevance Corporation. "Using information from the ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... in Brazil and ... guidelines and commonly prescribe long-acting beta-agonist (LABA)- and ... do so within current severe cost/coverage constraints. Therefore, ... are expected to launch in these countries—which will ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
(Date:8/23/2014)... 23, 2014 A team of New York ... longer when preceded by surgery and delivered by an experienced ... new study. Click here to read it now . ... cases of mesothelioma patients who underwent hemithoracic (one ... dose to the shape of a tumor. Patients who ...
(Date:8/23/2014)... 23, 2014 GBI Research, the leading ... Care Therapeutics in Major Developed Markets to 2020 - ... Drive Market”, which provides in-depth analysis of the critical ... Spain, Japan and Canada. The report provides an estimation ... to 2020. It covers critical care indications that are ...
(Date:8/23/2014)... Young adults in Athens, GA who find that they ... the phone and call the new helpline which can offer support ... , Troubled Teen Athens is a wonderful resource for an adolescent ... necessary steps to end substance abuse once and for all. When ... friends or peers when really they should put their faith in ...
(Date:8/23/2014)... NC (PRWEB) August 23, 2014 Teen substance ... young people in Holly Springs, NC. Countless adolescents throughout North ... regular basis. Unfortunately, many never receive professional rehab due ... adults on where to get help. Troubled Teens Holly Springs ... the lives of local teenage alcohol abusers in ...
(Date:8/22/2014)... 2014 2014 Deep Research Report ... and in-depth research report on the Glucose Meter ... including Glucose Meter definition, classification, application, and industry ... research covers the international market analysis, including domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3
... IRVINE, Calif., June 26 ISTA Pharmaceuticals, Inc. (Nasdaq: ... Ophthalmic Drugs Advisory Committee appointed by the U.S. Food ... (bepotastine besilate ophthalmic solution) 1.5% as an eye drop ... The Committee voted unanimously 7 to 0 in favor ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ), ... information in regards to our financial position in light of ... to the FDA action are currently being identified. The early ... $15 to $20 million. , , The products subject ...
... announced today that it will hold its 2009 Annual General ... Meeting of Shareholders (the "Special Meeting") on August 5, 2009. ... asked to vote in favor of certain matters related to ... Subject to shareholder approval and the approval of the ...
... , CASTRES, France, June ... Committee for Medicinal Products for Human Use,(CHMP), the ... has issued a positive opinion supporting approval and ... monotherapy in metastatic,treatment of bladder cancer (advanced or ...
... June 26 Today Sentry Data Systems, Inc. announced ... Pharmacy and Revenue Cycle Management application. Claims Guardian ... their bills for unusual, missing, or errant charges that ... , "We believe that automatically matching actual procurement ...
... Healthcare ... the second straight year. The list is sponsored by the Greater Omaha Chamber of Commerce and ... , ... Healthcare staffing company Medical Solutions has landed on the Best Places to ...
Cached Medicine News:Health News:Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen 2Health News:Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen 3Health News:Sentry Data Systems Announces Claims Guardian(TM) 2Health News:Sentry Data Systems Announces Claims Guardian(TM) 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: